Comparative mechanistic analysis of danicamtiv and omecamtiv mecarbil’s in vivo cardiac effects
Journal of General Physiology · 2025
DOI: 10.1085/jgp.202513762 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of General Physiology, 2025. Verfasst von Joshua B Holmes und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Urea, Heart. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, American Heart Association, National Heart Lung and Blood Institute.
Abstract (Originalsprache)
Danicamtiv is a second-generation myotropic sarcomere activator currently in clinical trials for treating heart failure with reduced ejection fraction. Initial clinical and preclinical studies suggest that danicamtiv improves upon the major shortcoming of the first-generation myotropic sarcomere activator, omecamtiv mecarbil (OM), which overly impaired diastolic function. However, no study has directly compared the in vivo cardiac effects of danicamtiv and OM to verify these claims. These direct comparisons are essential to understand the potential benefits of one drug over the other. Therefore, this study employed carefully controlled experiments with left ventricular pressure–volume loop and echocardiographic strain analysis to compare how danicamtiv and OM alter each phase of the cardiac cycle. Our results show that for similar increases in left ventricular stroke volume, danicamtiv reduced diastolic performance and myocardial relaxation less than OM. However, danicamtiv still significantly decreased diastolic function at higher doses, like OM. Furthermore, danicamtiv and OM elicited a qualitatively similar triphasic dose–response from the left ventricle. These similarities between danicamtiv and OM in the whole heart were surprising given recent evidence showing significant differences in the drugs’ molecular effects on myosin mechanics. We therefore conclude that danicamtiv likely has a wider therapeutic window than OM, but may be limited by the same trade-off between systolic and diastolic performance, driven by similar underlying mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, OH, USA.
ORCID-Profile: Joshua B Holmes, Julian E Stelzer
Förderung
- NHLBI NIH HHS
- American Heart Association
- National Heart Lung and Blood Institute
Zitieren
APA
Holmes, J. B., & Stelzer, J. E. (2025). Comparative mechanistic analysis of danicamtiv and omecamtiv mecarbil’s in vivo cardiac effects. Journal of General Physiology. https://doi.org/10.1085/jgp.202513762
Vancouver
Holmes JB, Stelzer JE. Comparative mechanistic analysis of danicamtiv and omecamtiv mecarbil’s in vivo cardiac effects. Journal of General Physiology. 2025. doi:10.1085/jgp.202513762
BibTeX
@article{Holmes2025,
author = {Holmes, Joshua B and Stelzer, Julian E},
title = {Comparative mechanistic analysis of danicamtiv and omecamtiv mecarbil’s in vivo cardiac effects},
journal = {Journal of General Physiology},
year = {2025},
doi = {10.1085/jgp.202513762}
}
EUVIMED